Published in Am J Pathol on April 01, 2003
Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol (2006) 3.19
The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med (2003) 2.94
Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J Am Soc Nephrol (2008) 2.74
Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes (2008) 2.41
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov (2009) 2.24
A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol (2008) 2.17
Molecular mechanisms of diabetic kidney disease. J Clin Invest (2014) 1.80
Knockdown of glyoxalase 1 mimics diabetic nephropathy in nondiabetic mice. Diabetes (2013) 1.74
RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol (2009) 1.72
Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev (2010) 1.66
Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci (2011) 1.60
Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med (Berl) (2009) 1.51
Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor. Kidney Int (2007) 1.42
Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes (2010) 1.32
Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol (2013) 1.31
Unlocking the biology of RAGE in diabetic microvascular complications. Trends Endocrinol Metab (2013) 1.30
Dynamic (re)organization of the podocyte actin cytoskeleton in the nephrotic syndrome. Pediatr Nephrol (2003) 1.25
RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. J Am Soc Nephrol (2008) 1.24
Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J (2009) 1.23
Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol (2010) 1.22
Receptor for advanced glycation end products and its involvement in inflammatory diseases. Int J Inflam (2013) 1.22
Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction. J Biol Chem (2010) 1.19
RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes (2008) 1.18
Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis. Ann N Y Acad Sci (2008) 1.17
Role of advanced glycation end products in cardiovascular disease. World J Cardiol (2012) 1.13
The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. Vascul Pharmacol (2012) 1.12
RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med (2007) 1.11
RAGE and the pathogenesis of chronic kidney disease. Nat Rev Nephrol (2010) 1.07
sRAGE induces human monocyte survival and differentiation. J Immunol (2010) 1.05
VEGF and podocytes in diabetic nephropathy. Semin Nephrol (2012) 1.02
Molecular mechanisms of diabetic vascular complications. J Diabetes Investig (2010) 1.01
RAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a murine model of pancreatic cancer. J Gastrointest Surg (2011) 1.00
A novel function of the receptor for advanced glycation end-products (RAGE) in association with tumorigenesis and tumor differentiation of HCC. Ann Surg Oncol (2007) 0.99
Diabetic peripheral neuropathy: should a chaperone accompany our therapeutic approach? Pharmacol Rev (2012) 0.99
Abeta-dependent Inhibition of LTP in different intracortical circuits of the visual cortex: the role of RAGE. J Alzheimers Dis (2009) 0.98
Mechanisms and consequences of TGF-ß overexpression by podocytes in progressive podocyte disease. Cell Tissue Res (2011) 0.98
Advanced glycation endproducts: from precursors to RAGE: round and round we go. Amino Acids (2010) 0.98
Advanced glycation end products: role in pathology of diabetic cardiomyopathy. Heart Fail Rev (2014) 0.97
Immune and inflammatory role in renal disease. Compr Physiol (2013) 0.97
Regulation of RAGE for attenuating progression of diabetic vascular complications. Exp Diabetes Res (2011) 0.97
High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrol Dial Transplant (2011) 0.97
Microglial receptor for advanced glycation end product-dependent signal pathway drives beta-amyloid-induced synaptic depression and long-term depression impairment in entorhinal cortex. J Neurosci (2010) 0.95
Uremic Toxicity of Advanced Glycation End Products in CKD. J Am Soc Nephrol (2015) 0.94
Reductive metabolism of AGE precursors: a metabolic route for preventing AGE accumulation in cardiovascular tissue. Diabetes (2009) 0.94
Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice. Diabetes (2012) 0.93
The receptor for advanced glycation end products is a central mediator of asthma pathogenesis. Am J Pathol (2012) 0.92
Pathogenesis and novel treatment from the mouse model of type 2 diabetic nephropathy. ScientificWorldJournal (2013) 0.92
Messenger RNA levels of podocyte-associated proteins in subjects with different degrees of glucose tolerance with or without nephropathy. BMC Nephrol (2013) 0.90
Paradoxical function for the receptor for advanced glycation end products in mouse models of pulmonary fibrosis. Int J Clin Exp Pathol (2011) 0.90
Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics. Amino Acids (2010) 0.90
Soluble RAGE blocks scavenger receptor CD36-mediated uptake of hypochlorite-modified low-density lipoprotein. FASEB J (2007) 0.88
Endogenous Secretory RAGE as a Novel Biomarker for Metabolic Syndrome and Cardiovascular Diseases. Biomark Insights (2007) 0.87
Below the radar: advanced glycation end products that detour "around the side". Is HbA1c not an accurate enough predictor of long term progression and glycaemic control in diabetes? Clin Biochem Rev (2005) 0.86
Immunohistochemical and electronmicroscopic features of mesenchymal-to-epithelial transition in human developing, postnatal and nephrotic podocytes. Histochem Cell Biol (2016) 0.85
Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovasc Diabetol (2015) 0.85
Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression. Cardiovasc Diabetol (2014) 0.85
Emerging Targets for Therapeutic Development in Diabetes and Its Complications: The RAGE Signaling Pathway. Clin Pharmacol Ther (2015) 0.85
Effects of atorvastatin on progression of diabetic nephropathy and local RAGE and soluble RAGE expressions in rats. J Zhejiang Univ Sci B (2011) 0.84
Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy. Adv Chronic Kidney Dis (2011) 0.84
Obesity in kidney disease: A heavyweight opponent. World J Nephrol (2014) 0.84
The Extract of Litsea japonica Reduced the Development of Diabetic Nephropathy via the Inhibition of Advanced Glycation End Products Accumulation in db/db Mice. Evid Based Complement Alternat Med (2013) 0.83
Cellular mechanisms and consequences of glycation in atherosclerosis and obesity. Biochim Biophys Acta (2016) 0.83
Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis. Lab Invest (2015) 0.82
Associations between structural and functional changes to the kidney in diabetic humans and mice. Life Sci (2013) 0.82
Glyceraldehyde-derived pyridinium (GLAP) evokes oxidative stress and inflammatory and thrombogenic reactions in endothelial cells via the interaction with RAGE. Cardiovasc Diabetol (2015) 0.81
RAGE signaling significantly impacts tumorigenesis and hepatic tumor growth in murine models of colorectal carcinoma. J Gastrointest Surg (2010) 0.81
Controlling the receptor for advanced glycation end-products to conquer diabetic vascular complications. J Diabetes Investig (2012) 0.81
Alternative splicing of the RAGE cytoplasmic domain regulates cell signaling and function. PLoS One (2013) 0.81
Effects of spironolactone and losartan on diabetic nephropathy in a type 2 diabetic rat model. Diabetes Metab J (2011) 0.80
Implications of treatment that target protective mechanisms against diabetic nephropathy. Semin Nephrol (2012) 0.79
Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune Diseases. Diagnostics (Basel) (2015) 0.79
-374 T/A RAGE polymorphism is associated with chronic kidney disease progression in subjects affected by nephrocardiovascular disease. PLoS One (2013) 0.78
The glomerulus--a view from the outside--the podocyte. Int J Biochem Cell Biol (2010) 0.78
Sesamin Ameliorates Advanced Glycation End Products-Induced Pancreatic β-Cell Dysfunction and Apoptosis. Nutrients (2015) 0.78
The multiple faces of RAGE - opportunities for therapeutic intervention in aging and chronic disease. Expert Opin Ther Targets (2015) 0.78
Promoting effects of the adipokine, apelin, on diabetic nephropathy. PLoS One (2013) 0.78
Inflammatory markers associated with osteoarthritis after destabilization surgery in young mice with and without Receptor for Advanced Glycation End-products (RAGE). Front Physiol (2013) 0.77
Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes. Mol Med (2015) 0.77
Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications. Mucosal Immunol (2016) 0.77
RAGE and TGF-β1 Cross-Talk Regulate Extracellular Matrix Turnover and Cytokine Synthesis in AGEs Exposed Fibroblast Cells. PLoS One (2016) 0.77
Soluble Receptor for Advanced Glycation End Product Ameliorates Chronic Intermittent Hypoxia Induced Renal Injury, Inflammation, and Apoptosis via P38/JNK Signaling Pathways. Oxid Med Cell Longev (2016) 0.77
Local and systemic RAGE axis changes in pulmonary hypertension: CTEPH and iPAH. PLoS One (2014) 0.77
Effects of olmesartan on arterial stiffness in rats with chronic renal failure. Cardiovasc Diabetol (2012) 0.77
ATP synthase subunit-β down-regulation aggravates diabetic nephropathy. Sci Rep (2015) 0.77
Renal-protective effect of nicousamide on hypertensive nephropathy in spontaneously hypertensive rats. Biomed Rep (2012) 0.77
Modulation of the cellular expression of circulating advanced glycation end-product receptors in type 2 diabetic nephropathy. Exp Diabetes Res (2011) 0.76
High Mobility Group Box Protein 1 Boosts Endothelial Albumin Transcytosis through the RAGE/Src/Caveolin-1 Pathway. Sci Rep (2016) 0.75
Association of the receptor for advanced glycation end-products (RAGE) gene polymorphisms in Malaysian patients with chronic kidney disease. PeerJ (2016) 0.75
A CF patient with progressive proteinuric renal disease: a CF-specific nodular glomerulosclerosis? NDT Plus (2010) 0.75
Nicousamide protects kidney podocyte by inhibiting the TGFβ receptor II phosphorylation and AGE-RAGE signaling. Am J Transl Res (2017) 0.75
Diabetes-Induced Reactive Oxygen Species: Mechanism of Their Generation and Role in Renal Injury. J Diabetes Res (2017) 0.75
Role of Neuropilin-1 in Diabetic Nephropathy. J Clin Med (2015) 0.75
A model of chronic diabetic polyneuropathy: benefits from intranasal insulin are modified by sex and RAGE deletion. Am J Physiol Endocrinol Metab (2017) 0.75
An explorative analysis of secretory receptor for advanced glycation endproducts in primary focal segmental glomerulosclerosis. Clin Exp Nephrol (2012) 0.75
Secretory products of macrophages. J Clin Invest (1987) 10.33
Transforming growth factor beta in tissue fibrosis. N Engl J Med (1994) 9.73
RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell (1999) 8.55
Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet (1982) 6.93
Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res (1997) 6.24
Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem (1992) 5.60
Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med (1998) 5.54
Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med (1984) 5.35
Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood (1996) 5.31
Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest (1997) 4.83
The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci (1996) 4.63
Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med (1990) 3.93
Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem (1994) 3.73
N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem (1999) 3.72
Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem (1992) 3.64
Pathophysiology of progressive nephropathies. N Engl J Med (1998) 3.61
Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A (2000) 3.48
Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A (1993) 3.16
The S100 protein family: history, function, and expression. Brain Res Bull (1995) 3.16
End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis (1999) 3.00
Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab (2001) 2.91
Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia (1999) 2.55
Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem (1997) 2.53
Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest (1997) 2.48
Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes (1996) 2.42
Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest (2001) 2.20
N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry (1995) 2.19
Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes (1999) 2.16
Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis [seecomments]. Kidney Int (1999) 2.13
Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest (2001) 2.07
Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol (2000) 1.92
Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest (1998) 1.85
Induction of differentiation in cultured rat and human podocytes. J Am Soc Nephrol (1997) 1.83
Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest (2000) 1.82
Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int (2000) 1.79
The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis (1993) 1.77
Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest (1997) 1.73
Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. Kidney Int (1998) 1.66
Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes (2000) 1.63
Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem (1997) 1.44
Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats. Lab Invest (2002) 1.44
Reactive oxygen species and neutrophil respiratory burst cytochrome b558 are produced by kidney glomerular cells in passive Heymann nephritis. Proc Natl Acad Sci U S A (1993) 1.29
Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int (2002) 1.24
Roles of the podocyte in glomerular function. Am J Physiol Renal Physiol (2000) 1.22
Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J Am Soc Nephrol (1997) 1.20
In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol (1998) 1.16
Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia (1999) 1.13
Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. Mol Cell Biol Res Commun (2000) 1.06
Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia (2001) 1.00
Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism (2001) 0.99
Alterations in the expression of the alpha 3 beta 1 integrin in certain membrane domains of the glomerular epithelial cells (podocytes) in diabetes mellitus. Diabetologia (1997) 0.99
Evolution of renal function abnormalities in the db/db mouse that parallels the development of human diabetic nephropathy. Exp Nephrol (1996) 0.93
Progression of diabetic nephropathy. Insights from cell culture studies and animal models. Kidney Blood Press Res (1999) 0.92
A potential role for angiotensin II-induced vascular endothelial growth factor expression in the pathogenesis of diabetic nephropathy? Miner Electrolyte Metab (1998) 0.91
Reduction of protein excretion by dimethyl sulfoxide in rats with passive Heymann nephritis. Kidney Int (1984) 0.90
Cell-mediated immunity in glomerular disease. Annu Rev Med (1991) 0.85
Prevention of decline in renal function in the diabetic db/db mouse. Diabetologia (1996) 0.84
Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects. Nephrol Dial Transplant (1997) 0.82
Interactions of dimethyl sulfoxide and nonsteroidal anti-inflammatory agents in passive Heymann's nephritis. J Lab Clin Med (1986) 0.80
DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature (2007) 13.56
Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol (2007) 8.33
The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol (2004) 7.38
Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation (2006) 5.31
RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med (2003) 5.14
Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol (2005) 4.99
Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) (2005) 4.96
The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int (2004) 4.77
Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis (2004) 4.20
Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest (2004) 4.04
Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res (2004) 4.00
RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation (2002) 3.93
Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest (2004) 3.89
HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature (2009) 3.86
A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci U S A (2003) 3.82
A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A (2010) 3.80
Professional antigen-presentation function by human gammadelta T Cells. Science (2005) 3.77
Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med (2009) 3.70
High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation (2008) 3.46
Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med (2007) 3.35
Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med (2012) 3.31
Regulation of innate immune responses by DAI (DLM-1/ZBP1) and other DNA-sensing molecules. Proc Natl Acad Sci U S A (2008) 3.27
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 3.15
Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest (2008) 3.11
Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature (2008) 3.05
Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol (2005) 3.05
Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J Immunol (2006) 3.03
Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int (2010) 2.95
The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med (2003) 2.94
C3 glomerulopathy: consensus report. Kidney Int (2013) 2.85
Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol (2012) 2.83
The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest (2005) 2.80
Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol (2006) 2.75
Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology (2005) 2.74
Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med (2003) 2.61
Very low birth weight is a risk factor for secondary focal segmental glomerulosclerosis. Clin J Am Soc Nephrol (2008) 2.57
Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing. Hum Pathol (2004) 2.53
RAGE signaling sustains inflammation and promotes tumor development. J Exp Med (2008) 2.51
Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features. Kidney Int (2003) 2.47
Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol (2009) 2.45
A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J (2007) 2.44
Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int (2011) 2.43
Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes (2008) 2.41
Multiple chronic pain states are associated with a common amino acid-changing allele in KCNS1. Brain (2010) 2.41
Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest (2003) 2.40
Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis. Kidney Int (2004) 2.39
ANCA-associated glomerulonephritis in the very elderly. Kidney Int (2010) 2.36
Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure. J Am Soc Nephrol (2005) 2.36
Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res (2002) 2.35
RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis (2008) 2.33
Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci U S A (2006) 2.31
Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. Mol Immunol (2004) 2.30
C3 glomerulopathy masquerading as acute postinfectious glomerulonephritis. Am J Kidney Dis (2012) 2.28
Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. Eur Heart J (2008) 2.26
Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock (2009) 2.26
Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res (2003) 2.25
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov (2009) 2.24
Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab (2013) 2.20
The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res (2010) 2.19